Enanta Pharmaceuticals Inc (ENTA)

$13.74

+0.49

(+3.7%)▲

Market is closed - opens 7 PM, 01 May 2024

Insights on Enanta Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 18.93M → 18.00M (in $), with an average decrease of 4.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -28.10M → -33.40M (in $), with an average decrease of 18.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 53.3% return, outperforming this stock by 116.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.0% return, outperforming this stock by 319.9%

Performance

  • $12.87
    $14.09
    $13.74
    downward going graph

    6.31%

    Downside

    Day's Volatility :8.6%

    Upside

    2.45%

    downward going graph
  • $8.08
    $37.27
    $13.74
    downward going graph

    41.19%

    Downside

    52 Weeks Volatility :78.32%

    Upside

    63.13%

    downward going graph

Returns

PeriodEnanta Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
3.68%
-1.3%
0.0%
6 Months
48.38%
12.4%
0.0%
1 Year
-64.68%
4.6%
0.0%
3 Years
-75.05%
15.7%
-21.9%

Highlights

Market Capitalization
273.3M
Book Value
$9.07
Earnings Per Share (EPS)
-6.57
PEG Ratio
0.0
Wall Street Target Price
22.29
Profit Margin
-187.77%
Operating Margin TTM
-193.78%
Return On Assets TTM
-22.89%
Return On Equity TTM
-56.11%
Revenue TTM
73.6M
Revenue Per Share TTM
3.5
Quarterly Revenue Growth YOY
-23.7%
Gross Profit TTM
86.2M
EBITDA
-139.6M
Diluted Eps TTM
-6.57
Quarterly Earnings Growth YOY
-0.66
EPS Estimate Current Year
-5.09
EPS Estimate Next Year
-4.67
EPS Estimate Current Quarter
-1.22
EPS Estimate Next Quarter
-1.25

Analyst Recommendation

Buy
    60%Buy
    33%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Enanta Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
5
5
5
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 62.23%

Current $13.74
Target $22.29

Company Financials

FY18Y/Y Change
Revenue
206.6M
↑ 100.97%
Net Income
72.0M
↑ 306.3%
Net Profit Margin
34.82%
↑ 17.59%
FY19Y/Y Change
Revenue
205.2M
↓ 0.69%
Net Income
46.4M
↓ 35.54%
Net Profit Margin
22.6%
↓ 12.22%
FY20Y/Y Change
Revenue
122.5M
↓ 40.31%
Net Income
-36.2M
↓ 177.98%
Net Profit Margin
-29.53%
↓ 52.13%
FY21Y/Y Change
Revenue
97.1M
↓ 20.74%
Net Income
-79.0M
↑ 118.41%
Net Profit Margin
-81.38%
↓ 51.85%
FY22Y/Y Change
Revenue
86.2M
↓ 11.24%
Net Income
-121.8M
↑ 54.13%
Net Profit Margin
-141.31%
↓ 59.93%
FY23Y/Y Change
Revenue
79.2M
↓ 8.07%
Net Income
-133.8M
↑ 9.91%
Net Profit Margin
-168.95%
↓ 27.64%
Q3 FY22Q/Q Change
Revenue
20.3M
↑ 4.3%
Net Income
-26.3M
↓ 16.88%
Net Profit Margin
-129.68%
↑ 33.06%
Q4 FY22Q/Q Change
Revenue
23.6M
↑ 16.09%
Net Income
-29.0M
↑ 10.01%
Net Profit Margin
-122.9%
↑ 6.78%
Q1 FY23Q/Q Change
Revenue
17.8M
↓ 24.55%
Net Income
-37.7M
↑ 29.92%
Net Profit Margin
-211.62%
↓ 88.72%
Q2 FY23Q/Q Change
Revenue
18.9M
↑ 6.16%
Net Income
-39.1M
↑ 3.74%
Net Profit Margin
-206.78%
↑ 4.84%
Q3 FY23Q/Q Change
Revenue
18.9M
↑ 0.21%
Net Income
-28.1M
↓ 28.05%
Net Profit Margin
-148.46%
↑ 58.32%
Q4 FY23Q/Q Change
Revenue
18.0M
↓ 4.91%
Net Income
-33.4M
↑ 18.86%
Net Profit Margin
-185.56%
↓ 37.1%
FY18Y/Y Change
Total Assets
414.2M
↑ 26.82%
Total Liabilities
20.5M
↓ 17.68%
FY19Y/Y Change
Total Assets
489.8M
↑ 18.25%
Total Liabilities
27.3M
↑ 33.04%
FY20Y/Y Change
Total Assets
486.1M
↓ 0.75%
Total Liabilities
30.6M
↑ 11.76%
FY21Y/Y Change
Total Assets
438.8M
↓ 9.74%
Total Liabilities
39.4M
↑ 28.84%
FY22Y/Y Change
Total Assets
375.4M
↓ 14.44%
Total Liabilities
54.1M
↑ 37.38%
FY23Y/Y Change
Total Assets
462.3M
↑ 23.14%
Total Liabilities
245.5M
↑ 354.06%
Q3 FY22Q/Q Change
Total Assets
375.4M
↓ 2.55%
Total Liabilities
54.1M
↑ 14.59%
Q4 FY22Q/Q Change
Total Assets
347.5M
↓ 7.43%
Total Liabilities
46.7M
↓ 13.65%
Q1 FY23Q/Q Change
Total Assets
326.4M
↓ 6.07%
Total Liabilities
57.1M
↑ 22.21%
Q2 FY23Q/Q Change
Total Assets
495.2M
↑ 51.69%
Total Liabilities
257.4M
↑ 350.94%
Q3 FY23Q/Q Change
Total Assets
462.3M
↓ 6.64%
Total Liabilities
245.5M
↓ 4.59%
Q4 FY23Q/Q Change
Total Assets
428.5M
↓ 7.31%
Total Liabilities
236.6M
↓ 3.63%
FY18Y/Y Change
Operating Cash Flow
29.2M
↓ 44.5%
Investing Cash Flow
-35.4M
↑ 674.32%
Financing Cash Flow
4.4M
↑ 333.53%
FY19Y/Y Change
Operating Cash Flow
71.4M
↑ 144.41%
Investing Cash Flow
-86.7M
↑ 144.8%
Financing Cash Flow
2.6M
↓ 41.62%
FY20Y/Y Change
Operating Cash Flow
7.1M
↓ 90.08%
Investing Cash Flow
19.8M
↓ 122.88%
Financing Cash Flow
9.0M
↑ 248.99%
FY21Y/Y Change
Operating Cash Flow
-70.0M
↓ 1087.53%
Investing Cash Flow
37.0M
↑ 86.54%
Financing Cash Flow
3.1M
↓ 65.71%
FY22Y/Y Change
Operating Cash Flow
-84.8M
↑ 21.12%
Investing Cash Flow
54.9M
↑ 48.41%
Financing Cash Flow
20.0M
↑ 550.42%
Q3 FY22Q/Q Change
Operating Cash Flow
-15.5M
↓ 47.52%
Investing Cash Flow
28.2M
↑ 74.05%
Financing Cash Flow
2.9M
↓ 28.88%
Q4 FY22Q/Q Change
Operating Cash Flow
-35.6M
↑ 129.44%
Investing Cash Flow
33.6M
↑ 18.91%
Financing Cash Flow
301.0K
↓ 89.73%
Q1 FY23Q/Q Change
Operating Cash Flow
-13.8M
↓ 61.33%
Investing Cash Flow
46.8M
↑ 39.31%
Financing Cash Flow
-2.0M
↓ 773.42%
Q2 FY23Q/Q Change
Operating Cash Flow
-32.1M
↑ 133.1%
Investing Cash Flow
-145.7M
↓ 411.66%
Financing Cash Flow
199.9M
↓ 9960.63%

Technicals Summary

Sell

Neutral

Buy

Enanta Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc
-22.15%
48.38%
-64.68%
-75.05%
-84.49%
Moderna, Inc.
Moderna, Inc.
4.46%
46.48%
-17.31%
-40.0%
317.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.11%
12.56%
10.41%
82.28%
161.35%
Novo Nordisk A/s
Novo Nordisk A/s
-0.53%
29.89%
51.57%
236.82%
416.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.58%
6.36%
13.86%
80.23%
127.58%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc
NA
NA
0.0
-5.09
-0.56
-0.23
NA
9.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc
Buy
$273.3M
-84.49%
NA
-187.77%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
317.84%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
161.35%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
416.51%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
127.58%
28.81
36.68%

Institutional Holdings

  • Armistice Capital, LLC

    9.76%

  • Farallon Capital Management, L.L.C.

    9.57%

  • BlackRock Inc

    9.15%

  • Vanguard Group Inc

    8.48%

  • Morgan Stanley - Brokerage Accounts

    5.54%

  • BRAIDWELL LP

    4.91%

Corporate Announcements

  • Enanta Pharmaceuticals Inc Earnings

    Enanta Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Organization
Enanta Pharmaceuticals Inc
Employees
145
CEO
Dr. Jay R. Luly Ph.D.
Industry
Health Technology

Discover More

FAQs